Page 764«..1020..763764765766..770780..»

JSP191 With Low Dose Irradiation and Chemotherpy Demonstrates Efficacy and Safety in MRD+ AML/MDS – Targeted Oncology

Posted: February 9, 2021 at 4:51 pm

In older adult patients undergoing nonmyeloablative allogeneic hematopoietic cell transplantation (HCT), treatment with JSP191 combined with low dose total body irradiation (TBI) and fludarabine appears safe, well-tolerated treatment option capable of clearing minimal residual disease (MRD)positivity, according to a poster presented during the 2021 Transplantation and Cellular Therapy Meetings.

While the results of this phase 1 trial (NCT04429191) are early, the investigators emphasized that these data are the first to demonstrate that the antiCD117 monoclonal antibody is safe and effective in this disease cohort.

We are developing a first-in-class monoclonal antibody (mAb), JSP191, which targets and depletes normal and MDS/AML disease-initiating hematopoietic stem cells, wrote the investigators. JSP191 acts by inhibiting stem cell factor binding to CD117 present on HSC. We and others showed in pre-clinical models that HSC depletion can be enhanced by combining anti-CD117 mAb with low dose total body radiation.

The anti-CD117 monoclonal antibody was administered to a total of 6 patients intravenously at a dose of 0.6 mg/kg. Of note, the study population consisted of patients aged 60 years or older with MRD detected via cytogenetics, difference from normal flow cytometry, or next-generation sequencing (NGS).

The dual primary end points of the study are the safety and tolerability of JSP191 combined with low dose total body radiation and fludarabine and of JSP191 pharmacokinetics. The secondary end points include engraftment and donor chimerism, MRD clearance, event-free survival, and overall survival, among others.

The team used serum concentration of JSP191 determined by pharmacokinetics to establish the predicted JSP191 clearance and safety for the administration of fludarabine at 30 mg/m2 per day for 3 days, at days 4, -3, and -2 leading up to transplant.

At 28 days following transplant, 5 out of 6 patients showed signs of complete (>95%) donor CD15 myeloid chimerism in the peripheral blood.

To this point, there has been no evidence of significant infusion toxicities or JSP191-related serious adverse events. Also, a reduction or elimination of MRD in all subjects was seen at 28 days following transplant.

The research team explained that blood stem cell transplantation may offer the only curative therapy for many forms of both AML and MDS. Even though the current standard-of-care conditioning regimens administered before blood stem cell transplantation are well tolerated, they remain associated with increased relapse rates due to the prevalence of disease-causing hematopoietic stem cells and inadequate graft versus leukemia effect.

Further accrual for this study continues, while correlative analyses focusing on JPS191s impact with disease-initiating hematopoietic stem cells are ongoing.

References:

Muffly L, Kwon HS, Chin M, et al. Phase 1 study of JSP191, an anti-CD117 monoclonal antibody, with low dose irradiation and fludarabine in older adults with MRD-positive AML/MDS undergoing allogeneic HCT. Presented at the 2021 Transplantation and Cellular Therapy Meetings, held February 8-12, 2021. Abstract LBA5.

Link:
JSP191 With Low Dose Irradiation and Chemotherpy Demonstrates Efficacy and Safety in MRD+ AML/MDS - Targeted Oncology

Posted in Stem Cell Research | Comments Off on JSP191 With Low Dose Irradiation and Chemotherpy Demonstrates Efficacy and Safety in MRD+ AML/MDS – Targeted Oncology

The International Parkinson and Movement Disorder Society (MDS) Continues to Caution Against Unproven Cell-Based Therapies for Parkinson’s Disease -…

Posted: February 9, 2021 at 4:51 pm

MDS hopes to stop this practice by educating the public on the importance of participating only in studies at accredited research institutions.

MILWAUKEE (PRWEB) February 09, 2021

The International Parkinson and Movement Disorder Societys Scientific Issues Committee (MDS-SIC), led by Stella Papa and Un Jung Kang, has commissioned a brief review of the current place of cell-based therapies for Parkinsons disease (PD), and ultimately encourages patients to participate only in cell therapy studies that are part of a research program affiliated with a recognized academic or clinical institution.

Theoretically, cell-based therapies, including the use of stem cells, could be used to replace or repair the cells lost or damaged in the disease process, thereby improving symptoms. While advances in cell-based research may ultimately provide potential new therapies for patients with PD, science has yet to fully establish a number of challenging aspects of stem cell therapy including specific cell type, method of administration, clinical effect and long-term safety.

Several business enterprises worldwide offer stem cell therapies for PD, making unsubstantiated claims of considerable benefit to the patient. Due to the potential for very serious side effects, the Society cautions patients to avoid any treatments carried out without adequate scientific research, and encourages patients to participate only in cell therapies affiliated with a recognized research institution.

MDS President, Claudia Trenkwalder, adds, This timely statement is an excellent scientific summary of the risks for persons with Parkinsons disease when selecting a treatment offering which is not scientifically, but purely economically driven. MDS hopes to stop this practice by educating the public on the importance of participating only in studies at accredited research institutions.

Read the full MDS statement and position paper cautioning against unproven cell-based therapies for Parkinson's disease.

About the International Parkinson and Movement Disorder Society: The International Parkinson and Movement Disorder Society (MDS), an international society of over 10,000 clinicians, scientists, and other healthcare professionals, is dedicated to improving patient care through education and research. For more information about MDS, visit http://www.movementdisorders.org.

Share article on social media or email:

See the article here:
The International Parkinson and Movement Disorder Society (MDS) Continues to Caution Against Unproven Cell-Based Therapies for Parkinson's Disease -...

Posted in Stem Cell Research | Comments Off on The International Parkinson and Movement Disorder Society (MDS) Continues to Caution Against Unproven Cell-Based Therapies for Parkinson’s Disease -…

NASA grants renewal and funding for deep space health protections – Baylor College of Medicine News

Posted: February 9, 2021 at 4:51 pm

After a favorable program review in December 2020, NASA has exercised its option to renew the Houston-based Translational Research Institute for Space Health (TRISH) until 2028. TRISH works closely with NASAs Human Research Program in advancing innovations in biomedical research to protect astronauts on deep space missions.

The Institute will receive additional funding up to $134.6 million from 2022 to 2028. It will continue delivering innovative solutions that mitigate health and performance decrements anticipated for humans in deep space, while advancing terrestrial health technologies.

Led by Baylor College of Medicines Center for Space Medicine, TRISH is a consortium that includes partners California Institute of Technology and Massachusetts Institute of Technology.

NASA has received outstanding value from our bold approach to sourcing and advancing space health research and technologies, said institute director Dr. Dorit Donoviel. We are proud to be NASAs partner in its human space exploration mission and to be supporting the research necessary to create new frontiers in healthcare that will benefit all humans.

Baylor College of Medicine was awarded the cooperative agreement from the NASA Human Research Program in 2016 to form TRISH. The Institute was tasked to find and fund innovative research, educate and disseminate space health information, develop a community of high-caliber scientists and provide leadership in the field of human health in deep space.

When NASA conducted its review of the Institute at the beginning of the fifth year of operations in December 2020, TRISH had:

The NASA Review Committee identified as strengths TRISHs ability to identify and support highly innovative or game-changing projects, its strong science team and the implementation of innovative approaches to collaboration.

In the next six years, TRISH will tackle three initiatives to bring future Mars exploration missions into clearer focus. First, TRISH will build strategic partnerships, including with commercial spaceflight companies, to increase the volume of available biometric data on the impact of space travel on health and performance.

In addition, TRISH is building a digital platform to simulate the spaceflight environment, which will allow researchers to model and test new health technologies without needing to leave Earth.

Finally, the Institute recognizes that the future of space exploration must include all humans. TRISH will leverage tissue chip technology to place a variety of human cells in lunar orbit as part of NASAs Artemis research missions. These personalized avatars will expand the possibilities of tracking the effects of space radiation and microgravity on human stem-cell derived mini-organs from different individuals.

Learn more about the Translational Research Institute for space Health at bcm.edu/spacehealth.

Read the original:
NASA grants renewal and funding for deep space health protections - Baylor College of Medicine News

Posted in Stem Cell Research | Comments Off on NASA grants renewal and funding for deep space health protections – Baylor College of Medicine News

Breakthrough stem cell therapy may reverse life-threatening conditions in dogs – Study Finds

Posted: February 7, 2021 at 12:54 am

SAKAI, Japan Just like humans, mans best friend deals with all sorts of chronic and degenerative conditions as they age. For dogs however, scientists have fewer ways of reversing life-threatening illnesses compared to human patients. Now, a team in Japan has successfully developed a technique which creates new stem cells from a dogs blood. Their study opens the door for new therapies which can regenerate a dogs body just like stem cells do in people.

In humans, these baby cells have the potential to grow into a variety of specialized cells, an ability called pluripotency. After scientists transplant these stem cells into a patient, they guide their differentiation into the specific kind of cells which completes their task. The new cells can then regenerate damaged tissues, reversing the effect of various diseases. While stem cell research for humans is a widely studied topic, researchers say little work is done with pets.

The new study, led by Associate Professor Shingo Hatoya from Osaka Prefecture University, focuses on induced pluripotent stem cells (iPSCs) in canine blood samples. Study authors say iPSCs are a type of stem cell which can be programmed from a developed cell. Scientists can do this by introducing specific genes into the cell. The genes code for specific proteins (transcription factors) which trigger the change from a developed cell into a pluripotent stem cell.

Another good thing about iPSCs is they multiply rapidly, providing a sustainable supply of usable stem cells for medical treatments.

We successfully established an efficient and easy generation method of canine iPSCs from peripheral blood mononuclear cells Dr. Hatoya in a university release.

The study authors call this a breakthrough in veterinary science. Hatoya hopes in the near future, it may be possible to perform regenerative medicinal treatments in dogs.

This isnt the first time scientists have experimented with iPSCs from canine blood cells. Researchers say these attempts used viral vectors to deliver the stem cell-triggering transcription factors.

In the new study, the Japanese team tested a different combination of factors to create pluripotency. Most importantly, researchers say they had to control how the reprogrammed cells multiplied in the host.

Scientists use viral vectors, which encode these transcription factors, to infect cells and convert them into iPSCs. Unfortunately, since these vectors merge with the hosts genetic material, these pluripotency factors can actually cause tumors if they are transplanted into a dog.

To avoid this, researchers created footprint-free stem cells using a special type of viral vector. This particular vector generates iPSCs without mixing with the hosts genes. It can also be automatically silenced by microRNAs in the cells. The OPU team grew these cells in a special environment which contained a small-molecule cocktail that enhances pluripotency. The results successfully produced cells which developed germ layers the basis of all organs.

Study authors say their findings provide a clear path to easy stem cell treatments for dogs. However, they add that their research may also have a ripple effect in the human medical world as well.

We believe that our method can facilitate the research involving disease modeling and regenerative therapies in the veterinary field, Dr. Hatoya says. Dogs share the same environment as humans and spontaneously develop the same diseases, particularly genetic diseases.

The team believes finding a cure for diseases in mans best friend may also open the door to curing illnesses still plaguing mankind.

The study appears in the journal Stem Cells and Development.

Read the original:
Breakthrough stem cell therapy may reverse life-threatening conditions in dogs - Study Finds

Posted in Stem Cell Therapy | Comments Off on Breakthrough stem cell therapy may reverse life-threatening conditions in dogs – Study Finds

Global Stem Cell Partnering Terms and Agreements Directory 2020: Company AZ, Headline Value, Stage of Development at Signing, Deal Component Type,…

Posted: February 7, 2021 at 12:54 am

Dublin, Feb. 05, 2021 (GLOBE NEWSWIRE) -- The "Global Stem Cell Partnering Terms and Agreements 2010-2020" report has been added to ResearchAndMarkets.com's offering.

The Global Stem Cell Partnering Terms and Agreements 2010-2020 report provides comprehensive understanding and unprecedented access to the stem cell partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter Stem Cell partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes.

This report provides details of the latest Stem Cell agreements announced in the life sciences since 2010.

The report takes the reader through a comprehensive review Stem Cell deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Stem Cell partnering deals.

The report presents financial deal term values for Stem Cell deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

One of the key highlights of the report is that over 650 online deal records of actual Stem Cell deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

A comprehensive series of appendices is provided organized by Stem Cell partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Stem Cell partnering and dealmaking since 2010.

Report scope

Stem Cell Partnering Terms and Agreements includes:

In Global Stem Cell Partnering Terms and Agreements 2010-2020, the available deals are listed by:

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Stem Cell dealmaking2.1. Introduction2.2. Stem Cell partnering over the years2.3. Most active Stem Cell dealmakers2.4. Stem Cell partnering by deal type2.5. Stem Cell partnering by therapy area2.6. Deal terms for Stem Cell partnering2.6.1 Stem Cell partnering headline values2.6.2 Stem Cell deal upfront payments2.6.3 Stem Cell deal milestone payments2.6.4 Stem Cell royalty rates

Chapter 3 - Leading Stem Cell deals3.1. Introduction3.2. Top Stem Cell deals by value

Chapter 4 - Most active Stem Cell dealmakers4.1. Introduction4.2. Most active Stem Cell dealmakers4.3. Most active Stem Cell partnering company profiles

Chapter 5 - Stem Cell contracts dealmaking directory5.1. Introduction5.2. Stem Cell contracts dealmaking directory

Chapter 6 - Stem Cell dealmaking by technology type

Chapter 7 - Partnering resource center7.1. Online partnering7.2. Partnering events7.3. Further reading on dealmaking

Appendices

For more information about this report visit https://www.researchandmarkets.com/r/c8ppmy

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Read the rest here:
Global Stem Cell Partnering Terms and Agreements Directory 2020: Company AZ, Headline Value, Stage of Development at Signing, Deal Component Type,...

Posted in Stem Cell Therapy | Comments Off on Global Stem Cell Partnering Terms and Agreements Directory 2020: Company AZ, Headline Value, Stage of Development at Signing, Deal Component Type,…

Stem cells’ efficacy confirmed in treating ototoxic hearing loss – Korea Biomedical Review

Posted: February 7, 2021 at 12:54 am

Researchers at the Catholic University of Korea St. Marys Hospital have recently proved the efficacy of bone marrow-derived stem cells to treat ototoxicity hearing loss, the hospital said Thursday.

The team, led by Professor Park Kyoung-ho of the Department of Otolaryngology, conducted an experiment on animal models with ototoxic sensorineural hearing, or sudden hearing loss.

They utilized Catholic MASTER cells, bone marrow stem cells developed by the Catholic Institute of Cell Therapy, to compare the stem cell injection group with the controlled group.

The result showed that animals started to recover their hearing after three weeks. Five weeks later, they recovered normal hearing at 8000Hz, 16000Hz and 32000Hz frequency.

Ototoxic hearing loss is caused when a person ingests chemicals or certain medications that adversely affect the inner ear functions. Major symptoms related to the illness are dizziness, false hearing, and hearing loss, which permanently defects hearing functions. Elders with such symptoms should have medical consultations as they are a high-risk group, the hospital said.

We have proved the efficacy of our bone marrow stem cells in recovering hearing, said Professor Park, who doubles as the director of the Stem Cell Institute. Through the results, we expect to provide new treatment opportunities for patients with hearing loss.

The test results were published in the Korean Journal of Otorhinolaryngology-Head and Neck Surgery.

Read the original post:
Stem cells' efficacy confirmed in treating ototoxic hearing loss - Korea Biomedical Review

Posted in Stem Cell Therapy | Comments Off on Stem cells’ efficacy confirmed in treating ototoxic hearing loss – Korea Biomedical Review

Stem Cell Therapy Market Information, Figures and Analytical Insights 2020 2026 – The Courier

Posted: February 7, 2021 at 12:54 am

The report contains an overview explaining Stem Cell Therapy Market on a world and regional basis. Global Stem Cell Therapy market report is a definitive source of information and provides the latest market research, evolving consumer trends with actionable information about new players, products, and technologies. Our analysts have statistical data to provide information about the statistical report, including the factors that drive and impede the market growth.

The study is an integrated effort of primary and secondary research. The report provides an overview of the key drivers affecting the generation and growth limitation of Stem Cell Therapy market. In addition, the report also examines competitive developments, such as mergers and acquisitions, new partnerships, new contracts, and new products in the world market. The past trends and future prospects presented in this report make it very comprehensible to market analysis. Furthermore, the latest trends, product portfolio, demography, geographic segmentation, and market regulatory framework Stem Cell Therapy were also included in the study.

Description:

Market Segment according to type covers:

Market segment by applications may be broken down into:

Request a sample report in PDF format@ https://www.regalintelligence.com/request-sample/201348

Fundamental Highlights

And More

The following section also highlights the supply-to-consumption gap. In addition to the above data, the growth rate of Stem Cell Therapy market in 2026 is also explained. Moreover, consumption charts by type and application are also given.

Purpose of Studies:

World Market Report Stem Cell Therapy Industry primarily covers 10 sections in the table as follows:

Complete the pre-order requisition form for the report: @ https://www.regalintelligence.com/enquiry/201348

Thank You.

See original here:
Stem Cell Therapy Market Information, Figures and Analytical Insights 2020 2026 - The Courier

Posted in Stem Cell Therapy | Comments Off on Stem Cell Therapy Market Information, Figures and Analytical Insights 2020 2026 – The Courier

Stem Cell Therapy Market Size, Top Key Players, Applications, Business Statistics, Trends and Forecast 2021-2027 The Bisouv Network – The Bisouv…

Posted: February 7, 2021 at 12:52 am

Fort Collins, Colorado: A new informative report on the Stem Cell Therapy Market has recently published by Reports Globe to its massive repository. The primary and secondary research techniques have been used to compile data from different sources such as websites, media publications, and press releases. The Stem Cell Therapy market offers up-to-date information on different market segments and sub-segments. It offers an all-inclusive study of different key factors affecting the growth of the Stem Cell Therapy market. The global market research report offers extensive research on different technologies, tools, and standard methodologies that are fueling the growth prospect of the Stem Cell Therapy market.

Global Stem Cell TherapyMarketwas valued at 117.66 million in 2019 and is projected to reach USD255.37 million by 2027, growing at a CAGR of 10.97% from 2020 to 2027.

The Stem Cell Therapy market is highly consolidated due to the presence of many companies operating in this sector. The report describes the current market position of these companies, their past performance, graphs of supply and demand, production and consumption patterns, distribution network, sales channels, and growth opportunities in the market. The main market candidates listed in the report are:

The global informative report begins with a brief introduction of Stem Cell Therapy market and market overview, classification, application, technologies, products or services, and key players operating across the globe. The global informative report elaborates on the global market scope, market scope at the present, and prediction of demand from global clients in the future. The global market research report has been presented in a clear and professional manner for easy and better understanding to readers. The driving forces, limitations, and global opportunities are listed for the Stem Cell Therapy market to get the gist of different dynamics of the global market. It has been compiled through proven research techniques such as primary research and secondary research.

Request a Discount on the report @ https://reportsglobe.com/ask-for-discount/?rid=33553

Market Segments and Sub-segments Covered in the Report are as per below:

1.Stem Cell Therapy Market, By Cell Source:

Adipose Tissue-Derived Mesenchymal Stem Cells Bone Marrow-Derived Mesenchymal Stem Cells Cord Blood/Embryonic Stem Cells Other Cell Sources

2.Stem Cell Therapy Market, By Therapeutic Application:

Musculoskeletal Disorders Wounds and Injuries Cardiovascular Diseases Surgeries Gastrointestinal Diseases Other Applications

3.Stem Cell Therapy Market, By Type:

Allogeneic Stem Cell Therapy Market, By Application Musculoskeletal Disorders Wounds and Injuries Surgeries Acute Graft-Versus-Host Disease (AGVHD) Other Applications Autologous Stem Cell Therapy Market, By Application Cardiovascular Diseases Wounds and Injuries Gastrointestinal Diseases Other Applications

Geographical scenario:

The geographical analysis of the Stem Cell Therapy market has been done by examining different global regions such as North America, Latin America, Middle East, Asia-Pacific, and Africa on the basis of different parameters. The primary target for the Stem Cell Therapy market are the Stem Cell Therapy countries. The Stem Cell Therapy market has broadly compiled through extensive research and analysis techniques such as qualitative and quantitative analysis. Furthermore, it offers a blend of SWOT and Porters five techniques to analyze the data of the global market. Moreover, this report offers a complete analysis of different business perspectives such as the ups and downs of the global market shares. To expand the market at the global level, it makes use of different techniques and sales methodologies for achieving the outcomes of the businesses.

Collectively, this research repository encapsulates data of Stem Cell Therapy market to offer strategic decision-making abilities to various investors, business owners, decision-makers as well as policymakers.

The Stem Cell Therapy Market is divided into the following regions:

North America (USA, Canada)Latin America (Chile, Brazil, Argentina, rest of Latin America)Europe (UK, Italy, Germany, France, rest of the EU)Asia Pacific (India, Japan, China, South Korea, Australia, rest of APAC)Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa, rest of MEA)

View market snapshot before purchasing @ https://reportsglobe.com/product/global-stem-cell-therapy-market/

Following major key questions are addressed through this global research report:

1. What will be the Stem Cell Therapy market size over the forecast period?2. What are the demanding regions for making significant growth in the upcoming future?3. What are the challenges in front of the Stem Cell Therapy market?4. Who are the key vendors in Stem Cell Therapy market?5. What are the effective sales patterns and methodologies for boosting the performance of the Stem Cell Therapy market?6. What are the different ways to find out potential customers as well as global clients?7. Which factors are hampering the Stem Cell Therapy market?8. What are the outcomes of SWOT and porters five techniques?9. What are the demanding trends of the Stem Cell Therapy market?

Key strategic developments in the Stem Cell Therapy market:

This global study also includes the key strategic developments of the Stem Cell Therapy market including the new product launchings, partnerships and collaboration among the key players functioning at the global level.

Request customization of the report @ https://reportsglobe.com/need-customization/?rid=33553

Key target audience for Stem Cell Therapy report:

The report is insightful documentation and provides significant insights to customers, business owners, decision-makers, providers, distributors, suppliers, policymakers, manufacturers, investors, and individuals who have a keen interest in the Stem Cell Therapy market.

How Reports Globe is different than other Market Research Providers:

The inception of Reports Globe has been backed by providing clients with a holistic view of market conditions and future possibilities/opportunities to reap maximum profits out of their businesses and assist in decision making. Our team of in-house analysts and consultants works tirelessly to understand your needs and suggest the best possible solutions to fulfill your research requirements.

Our team at Reports Globe follows a rigorous process of data validation, which allows us to publish reports from publishers with minimum or no deviations. Reports Globe collects, segregates, and publishes more than 500 reports annually that cater to products and services across numerous domains.

Contact us:

Mr. Mark Willams

Account Manager

US: +1-970-672-0390

Email: [emailprotected]

Web: reportsglobe.com

View original post here:
Stem Cell Therapy Market Size, Top Key Players, Applications, Business Statistics, Trends and Forecast 2021-2027 The Bisouv Network - The Bisouv...

Posted in Colorado Stem Cells | Comments Off on Stem Cell Therapy Market Size, Top Key Players, Applications, Business Statistics, Trends and Forecast 2021-2027 The Bisouv Network – The Bisouv…

More on deadly blizzards | TheFencePost.com – Fence Post

Posted: February 7, 2021 at 12:52 am

Kindly readers keep responding to my recent columns about advanced weather forecasting and the great Nebraska blizzard in 1888 that killed hundreds of school children who died from exposure trying to make to their prairie homes from their one-room schoolhouses.

This weeks response to those columns comes from Irene, the egg woman, with a family story about another deadly blizzard other than the one in 1888. Heres her story:

Your column on the 1888 blizzard in Nebraska reminded me of what my mother told me about a blizzard in early March of 1927. My mother, age 20, was the second of seven children. Her mother, my grandmother, was in the hospital at McCook, Neb., after giving birth to the seventh child.

The younger sister of my grandmother and her young son from Colorado were visiting the family on their farm about 30 miles from McCook. My mother, her aunt, her older brother, and her 4-year-old brother decided to visit my grandmother and the new baby at the hospital in McCook. The school-age children including the aunts son were left at the one-room country school.

When they began the trip home, it was snowing hard. They came upon two children trying to walk home, so they put them in the car and took them to the childrens home. As they proceeded after letting off the children at their home, the group realized they would not be able to reach their farm, so they went back to the house where they had left the children and asked to stay. The childrens father said, No. He gave no reason. There were two salesmen at the house, and they, too, were not allowed to stay.

The group, which now included the salesmen, decided to go back to the hospital in McCook. Soon the Model T would go no farther, so they began walking. One of the salesmen was carrying a heavy suitcase. It probably contained his wares. He refused to give it up, so my mother grabbed it and threw it into the ditch. After walking a while, my mother thought she saw the hospital on the other side of a field. The others thought she was hallucinating, but they followed her across the field. She had been correct. They knocked on the hospital door, however no one came, so my mother used her knee to break the glass. That got some attention, and my mother and her companions were given supper and warm beds.

Several years later the hospital suffered minor damage from a cyclone. The Catholic sisters who ran the hospital jokingly told my grandfather, We thought it was your daughter.

What happened to the children at school? The neighbors took them to their own homes. My mother told me no one worried about the children, as they knew the neighbors would take care of them. Would that happen in todays society?

***

I read an article recently where some bio-scientists were growing actual wood in their laboratory using a gene-manipulating technique similar to that of growing fake meat.

The scientists were making plant-growing cells similar to stem-cells in animals. Their basic cells came from a common flower. And then some way they were programming those cells to morph into tree wood cells.

As if that bit of science isnt crazy enuf to wrap your brain around, how about this? The scientists believe that ultimately they can grow the fake wood material into any size and shape they desire.

So, the future of buying one-piece wooden furniture might be to order a lab-grown chair or table direct from the fake wood store grown into the size/shape you order.

I swear I read the story. Ill leave it to you to believe it will happen sometime.

***

It wuz take your child to work day at the local short-line farm machinery factory where a young farmer worked as a welder during the day shift. The farmer/welders 8-year-old daughter was all excited about the visit and had been for weeks. In preparation to the visit, her dad had done his best to explain in advance all about his job, his work place and his co-workers.

On the big day, as the farmer/daughter pair were meandering around the factory floor, the daughter began to cry and get cranky.

Her concerned father bent over and asked his daughter what wuz wrong. The little gal continued sobbing so loudly that a group of co-workers gathered around.

Finally, the little gal sobbed out why she wuz so unhappy. She sobbed loudly, Daddy, where are all the goofy, ignorant clowns you said you worked with?

***

Ol Jay Esse from Colorado sends me lots of wise words to end my columns with. Heres a few off of his stack thats accumulated on my desk:

Life is too short to drive boring cars.

If a cow doesnt produce enuf milk, is she a milk dud or an udder failure?

Advice to men: You should always look both ways before crossing a woman.

Why do TV news reporters spend a half hour giving us bad news and, yet, end their programs by telling us to Have a good evening?

At my age Im old enough to not believe everything I read including the bathroom scales.

Have a good un.

See original here:
More on deadly blizzards | TheFencePost.com - Fence Post

Posted in Colorado Stem Cells | Comments Off on More on deadly blizzards | TheFencePost.com – Fence Post

Novel Bone Marrow ‘Ingredient’ To Help Arthritic Horses The Horse – TheHorse.com

Posted: February 7, 2021 at 12:50 am

Regenerative therapies such as stem cells and platelet-rich plasma already play an important role in managing osteoarthritis (OA). Nonetheless, veterinarians have found that response to even these therapies is less than ideal in many cases, prompting researchers to continuously seek novel therapies for this all-too-common musculoskeletal disorder. One of the newest to be unveiled is called bone marrow mononuclear cell (BMNC) therapy. One researcher who presented at the 2020 American Association of Equine Practitioners Convention, held virtually, reported that the equine industry is in critical need for therapies that resolve joint inflammation but preserve tissue healing, and BMNC appears a promising candidate.

Much more than stem cells classically sought for cartilage healing, bone marrow is rich in macrophage progenitor cells, explained James B. Everett, DVM, MS, previously of the Virginia-Maryland College of Veterinary Medicine, who now works at the Equine Surgical Center at ThorSport Farm,in Murfreesboro, Tennessee. Macrophages are a type of white blood cell that play a role in tissue repair and cartilage integrity, and produce the anti-inflammatory mediators, including interleukin-10 (IL-10).

Everett said macrophages in the synovial (joint) membrane are essential for joint health, clearing aggressors, secreting key molecules required for optimal joint function, and forming a shield that protects tissues undergoing repair, similar to a wound scab. However, when the amount of tissue damage overwhelms these housekeeping functions, macrophages stimulate inflammation as a means of recruiting more cells, especially more macrophages, to cope with increased demands for repair.

If this response is efficiently accomplished, macrophages then produce, among other things, high concentrations of IL-10 and resolve the inflammatory process, returning the joint to a healthy state, he said.

Everett emphasized that not all inflammation is bad. This acute inflammation is essential to establish a resolving response, and anti-inflammatory therapies can negatively interfere.

As presented by Everetts colleague Bruno Menarim, DVM, PhD, in a separate session, studies show that BMNCs promote the endogenous resolution of experimentally induced inflammation. To see if these promising features translated to naturally occurring inflammation in live horses, Everetts research team studied 19 horses, dividing them into three treatment groups:

The selected horses were diagnosed with OA in a single joint, and the team injected those joints once with the saline, triamcinolone, or BMNCs. The BMNCs were autologous, meaning veterinarians collected them from each patients own bone marrow aspirate. They processed the aspirate in-house, and the isolated mononuclear cells, composed predominantly of macrophages, were ready to inject into the affected joint within three hours of aspiration.

We found that while objectively assessed lameness (via Lameness Locator) decreased in all three groups, it was only significant in the BMNC-treated horses, said Everett. Further, the treatment was well-tolerated with no adverse events appreciated in this study.

He said that using BMNCs can help reduce the need for chronic use of non-steroidal anti-inflammatory drugs and corticosteroids, which produces potentially harmful consequences. Further, BMNCs preserve the production of molecules such as interleukins and cytokines that are essential for restoring joint homeostasis. Corticosteroids often inhibit these molecules.

The researchers noted that these results support a larger clinical trial using BMNCs in clinical cases of equine OA.

Read more here:
Novel Bone Marrow 'Ingredient' To Help Arthritic Horses The Horse - TheHorse.com

Posted in Virginia Stem Cells | Comments Off on Novel Bone Marrow ‘Ingredient’ To Help Arthritic Horses The Horse – TheHorse.com

Page 764«..1020..763764765766..770780..»